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Abstract 
Aim: MRI-detected extramural venous invasion (mrEMVI) is a poor prognostic factor 
in rectal cancer. Pre-operative chemoradiotherapy (CRT) can cause regression in 
the severity of EMVI and subsequently improve survival whereas  mrEMVI persisting 
after CRT confers an increased risk of recurrence. The effect of adjuvant 
chemotherapy (AC) following CRT on survival in rectal cancer remains unclear. The 
aim of this study was to determine whether there is a survival advantage for AC 
given to patients with mrEMVI persisting after CRT. 
Method: A prospective analysis was conducted of consecutive patients with locally-
advanced rectal cancer between 2006-2013. All patients underwent CRT followed by 
surgery. AC was given to selected patients based on the presence of specific ‘high-
risk’ features. Comparison was made between patients offered AC with observation 
alone. The primary outcome was three -year disease-free survival (DFS). 
Results: 227 (36.0%) of 631 patients demonstrated persistent mrEMVI following 
CRT. Patients were grouped on the basis of AC or observation and were matched 
for age, performance status and final histopathological staging. Three-year DFS in 
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the AC group was 74.6% compared with 53.7% in the observation only group. AC 
had a survival benefit on multivariate analysis (HR 0.458; 95%CI 0.271-0.775 
p=0.004).  
Conclusion: Patients with persistent mrEMVI following CRT who receive AC may 
have a decreased risk of recurrence and an improved three-year DFS compared with 
patients not receiving AC, irrespective of age and performance status. 
 
What does this paper add to the literature? 
The paper provides further evidence that MRI-detected EMVI in rectal cancer after 
preoperative chemoradiotherapy is associated with a poor prognosis. It should be an 
indication for adjuvant chemotherapy despite the  current lack of consensus.  
 
Introduction 
MRI-detected extramural venous invasion (mrEMVI) is a poor prognostic factor in 
rectal cancer associated with poor survival (1, 2). Persistent mrEMVI following pre-
operative chemoradiotherapy (CRT) is associated with an increased risk of 
recurrence (3-5) (Figure 1). Conversely, when there is MRI evidence of fibrosis in the 
extramural veins and regression of venous disease, survival is improved (6) 
suggesting that patients with persistent mrEMVI are a ‘high-risk’ group for treatment 
failujre.  Stage II tumours with EMVI have been shown to have a similar survival as 
stage III tumours following CRT (7).  
The role and timing of adjuvant chemotherapy in rectal cancer is contentious and the 
evidence-base is lacking compared with colon cancer (8). The QUASAR trial (9) still 
provides the only robust evidence for adjuvant chemotherapy in rectal cancer. 
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Furthermore, the effect of adjuvant chemotherapy for patients who have already 
undergone CRT is even less clear.  
Adjuvant chemotherapy is the main oncological treatment to improve long-term 
survival although its optimal timing and patient selection are still not clear. The aim of 
the present study was to determine whether there is a survival advantage from 
adjuvant chemotherapy in patients with persistent mrEMVI following CRT. 
Method    
Patients  
The study was carried out following internal review of the study proposal by the 
Department of Clinical Research and Development at The Royal Marsden Hospital.  
Patients were identified from a prospectively maintained database. Data were 
extracted on consecutive patients undergoing curative treatment for locally advanced 
rectal cancer between January 2006 and January 2013. Treatment included long-
course neoadjuvant chemoradiotherapy followed by surgery. Adjuvant chemotherapy 
was offered to selected patients an informed discussion based on the presence or 
absence of specific adverse or ‘high-risk’ features including nodal disease, 
increasing tumour penetration into the mesorectum, threat of involvement of the 
circumferential resection margin. Patients with synchronous tumours, undergoing 
local excision and those treated by palliative surgery were excluded. There was a 
central review of all pathology and radiology by specialised gastrointestinal 
pathologists and radiologists. 
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Staging and neoadjuvant therapy 
All patients were staged by clinical rectal examination, colonoscopy, high-resolution 
magnetic resonance imaging (MRI) of the rectum and computed tomography (CT) of 
the thorax, abdomen and pelvis. All treatment decisions were made during a 
multidisciplinary team meeting. Our policy has been to offer long-course pre-
operative chemoradiotherapy (54Gy in 2 Gy fractions with concominant 5-fluorouracil 
based chemotherapy) to patients with any of the following features:  tumour within 1 
millimetre (mm) of the mesorectal fascia or bordering the intersphincteric plane 
(potential circumferential resection margin involvement), MRI-detected EMVI, 
extramural tumour spread of more than 5mm, and N2 nodal disease (metastasis in 
four or more regional lymph nodes). Patients were fully restaged with MRI following 
completion of preoperative chemoradiotherapy. Restaging MRI was used to 
determine the presence of persisting EMVI and formed the basis of the patient group 
for the study.  
 
Adjuvant chemotherapy regime   
The decision to advise chemotherapy following surgery was made during the 
multidisciplinary meeting. Not all patients were offered the same regime which was 
determined following informed discussion. No regime lasted longer than six months 
unless there was progression of disease with a view towards palliation. The regimes 
can be divided into i) Capecitabine; ii) Capecitabine and Oxaliplatin; iii) 5-FU based; 
iv) Folinic acid, 5-FU and Oxaliplatin; v) Other. All adjuvant treatment was started 
within six weeks of surgery. 
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Outcome 
The primary outcome was 3-year disease-free survival from the date of surgery. The 
main secondary outcome was recurrence which was defined by radiological or 
histological evidence of disease and confirmed on multidisciplinary discussion.  
 
Definitions 
Performance status was defined according to the Eastern Cooperative Oncology 
Group (ECOG) classification. Evidence of mrEMVI was confirmed on T2-weighted 
images and seen as a serpiginous or tortuous linear structure. Assessment of 
mrEMVI included the following: pattern of tumour margin (extension into small veins 
may produce a nodular border), location of tumour relative to major vessels, vessel 
calibre (tumour causes vessel expansion and increase in tumour signal in the lumen) 
and vessel border. Smaller venules can be seen perforating the outer rectal wall and 
produce a low to intermediate signal intensity in tubular structures on T2-weighted 
images. Venous invasion into these can be seen recognised by their enlargement 
and irregularity adjacent to the tumour due to contiguous tumour extension. 
A positive resection margin was defined as tumour within 1mm of the circumferential 
resection margin in the surgical specimen. Staging was performed according the 5th 
Edition of the Tumour, Node, Metastasis (TNM) system from the American Joint 
Committee on Cancer and was based on the final pathological findings. Stage II 
disease is classified as T1-4, N0, M0 and stage III as T1-4, N1-2, M0. Disease free 
survival (DFS) was the time from the date of surgery to the date of pelvic recurrence 
and/or distant disease or death due to pelvic recurrence and/or distant disease.  
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Statistical analysis  
Differences between groups were assessed using Pearson’s chi-squared test or 
Fisher’s Exact test as appropriate. Survival estimates of the disease free survival 
(DFS) were obtained using the Kaplan-Meier product limit method. Patients were 
censored at the last point of known contact or if they died during follow-up without 
experiencing the outcome of interest.  
Cox’s proportional hazard models were built to test the impact of confounding 
variables on survival such as age, gender, performance status, pathological T-stage 
and N stage and CRM involvement. These models allowed the effect of predictive 
factors on outcome to be assessed, accounting for censored outcome, differing time 
of follow-up and the interval between surgery and the adverse event of interest. 
Hazard ratios (HR) and 95% confidence intervals (CI) were generated. In order to 
provide clinically and meaningful risk adjustment, a fully adjusted model was used. 
All predictive risk factors that were judged to be clinically relevant were entered into 
a fixed model to adjust the impact of adjuvant chemotherapy on survival. Data were 
analysed using SPSS 21 (SPSS Inc, Chicago, Illinois) and Excel 2013. 
Results 
Demographics and treatment  
Of 631 patients, 227 (36.0%) had evidence of persistent mrEMVI following CRT. The 
median age was 63.5 (IQR: 54.8- 72) years. 158 patients had undergone adjuvant 
chemotherapy with 69 being observed following surgery. Demographic and tumour 
characteristics are shown in Table 1. 
\ 
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Histopathological staging  
Most patients had advanced disease, T stages 3 and 4. Involvement of the regional 
lymph nodes was less common being present in less than third of patients showing 
histopathological evidence of malignant nodes following CRT. Only 14 (6.2%) 
patients had a positive CRM after surgery.  
  
Comparison of adjuvant chemotherapy and observation (non-chemotherapy) groups  
Patients were grouped according to whether or not they had received adjuvant 
chemotherapy. Their demographic and tumour characteristics are shown in Table 3. 
Both groups were matched for age, performance status and final histopathological 
staging including T- and N-stage, and CRM status. Most (206 [90.7%]) patients in 
each group were of performance status 0 or 1 with a locally advanced T-stage. Table 
4 shows the different chemotherapy regimes offered to patients. 
 
Survival analysis 
At a median follow-up of 26 (2-84) months there were 68 recurrences of which 12 
(17.6%) were local. These included 10 local and 34 distant recurrences in the AC 
group and 2 local and 22 distant in the observation group . The three year DFS for 
patients who received adjuvant chemotherapy was 74.6% and observation only 
53.7% (Figure 2). There was a significant difference in disease-free survival using 
the Mantel Cox Log Rank Test – p=0.02. On multivariate analysis, CRM involvement 
was a significant factor for a reduced three year DFS (HR 3.891; 95%CI 1.642-
9.174).  
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For the purposes of analysis, patients who received adjuvant chemotherapy were 
used as reference to test the significance of chemotherapy on recurrence. Adjuvant 
chemotherapy had a survival benefit on multivariate analysis (HR 0.458; 95%CI 
0.271-0.775) (Table 3).  
 
Discussion 
The main finding of the present study was that patients with persistent mrEMVI who 
receive adjuvant chemotherapy following neoadjuvant chemoradiation had a reduced 
risk of developing disease recurrence. This was independent of age, performance 
status and nodal disease. The patients also had a significantly improved disease-
free survival at three years compared with those undergoing clinical follow-up alone 
(74.6% versus 53.7%). Although most patients had adjuvant chemotherapy, 
approximately 30% did not, implying that there was a significant number of patients 
who may have benefited from additional treatment but were currently being denied 
optimal treatment. It is notable that nodal disease was not an independent factor for 
recurrence in matched patients who had previously undergone neo-adjuvant 
treatment and oncologically successful surgery. CRM status was also shown to be a 
significant factor for disease relapse. 
There is a lack of consensus on the use of adjuvant chemotherapy following neo-
adjuvant chemoradiation (8, 10). The current European and North American 
guidelines recommend that all patients with stage III and ‘high-risk’ stage II rectal 
cancers are offered adjuvant chemotherapy although this is not based on robust 
evidence. The survival benefit of further treatment with up to six months of 5-FU-
based chemotherapy in patients who may have already had a significant response 
from pre-operative treatment is unknown and further confuses the issue. The 
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literature shows that patients who have had a minimal response to neoadjuvant 
treatment have no survival benefit following adjuvant chemotherapy (11-13). The 
PROCTOR/SCRIPT trial is a Dutch-Swedish collaborative phase III study of patients 
with stage II or III rectal cancer who have undergone pre-operative CRT and surgery. 
Comparison was made between those patients having adjuvant chemotherapy and 
those under observation only. A total of 437 patients were eligible for analysis with a 
median follow-up of five years. There was no difference in DFS, overall survival (OS) 
or recurrence (14). Bosset et al have recently published the long-term results from 
the well-known EORTC Trial 22921. In this, patients with T3 or T4 disease were 
assigned to chemotherapy or observation following pre-operative radiotherapy with 
or without sensitising chemotherapy. Again, there was no difference in DFS or OS at 
a median follow-up of 10.4 years. A recent meta-analysis also showed no survival 
benefit in patients with stage II and III disease following CRT (15) which would 
suggest that the results of the present study are at odds with the literature. The 
present study is, however, not directly comparable and highlights the difficulty in 
conducting trials involving adjuvant chemotherapy. 
This study investigated a specific high-risk factor rather than analysing the outcome 
of all patients who had undergone pre-operative treatment. The DFS of the 
observation group was much lower than in those studies which have looked at more 
general endpoints but this simply may demonstrate the high likelihood of recurrent or 
metastatic disease in patients with persistent EMVI. Previous studies have shown 
the increased risk of recurrence with EMVI (4, 7, 16) so it is not surprising that 
patients with persistent mrEMVI under observation only have a significant risk of 
developing metastases.  
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Risk stratification has evolved in recent years with increasing use of MRI in this area. 
There are, however, only limited reports of using MRI to specifically determine 
prognosis (16, 17). This is an area which requires further study and robust 
randomised trial evidence to determine which patients will most benefit from adjuvant 
chemotherapy as increasing numbers are undergoing ‘successful’ pre-operative 
treatment. A ‘blanket’ approach whereby all patients are routinely given adjuvant 
therapy may lead to substantial over-treatment with perhaps no survival benefit. The 
use of MRI in selecting high-risk patients may further improve future trial design 
allowing for treatment decisions to be made in conjunction with the pathology. 
This uncertainty has led to differences in practise with regard to the recommendation 
for  adjuvant chemotherapy (18). Khrizman et al have explored the reasons behind 
the variability in adjuvant chemotherapy and whether this is related to patient or 
tumour characteristics (19). They found that age, co-morbidity, performance status, 
operative complications and a complete pathologic response were significant factors 
for not receiving adjuvant chemotherapy. Age is most commonly cited as a reason 
for not recommending adjuvant treatment (20-22) but there is good evidence for 
comparable results for elderly patients who are given such treatment in both colonic 
and rectal cancer (23, 24). With an increasingly elderly population and a drive 
towards improving the outcome for this group of patients, there is very likely in the 
future to be a rise in the number of elderly patients being offered adjuvant treatment. 
Another interesting point is that comorbidity or performance status are often used as 
reasons why eligible patients did not receive adjuvant chemotherapy (25).  
The design of the present study and the subsequent analysis attempted to address 
some of these points which have previously explained the variability in practise with 
regard to adjuvant chemotherapy. mrEMVI is a ‘high-risk’ factor and patients should 
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be offered adjuvant treatment to reduce the risk of recurrence. While there are many 
reasons for patients to be offered or declined chemotherapy, those in the present 
study were matched for age, performance status and final staging which means the 
results of the multivariate analysis show a true independence for recurrence. All 
patients were of similar staging and received the same treatment apart from subtle 
variations in the specific adjuvant chemotherapy regime.   
mrEMVI is being increasingly recognised as a prognostic factor in rectal cancer(4, 7, 
26). It has been shown to be affected by neoadjuvant treatment and in those patients 
having a significant response there is an associated improvement in survival. MRI is 
thus being increasingly used as an imaging biomarker in rectal cancer, as 
demonstrated in initial small-scale study (6). There has been recent concern of the 
reliability of routine pathological analysis to detect EMVI accurately particularly after 
CRT when much of the architectural features which form the basis of its identification 
are lost by the fibrosing effect of CRT (27). Using the MRI characteristics to guide 
and inform adjuvant treatment decision-making is becoming more prevalent  and is 
already universally done with regard to neoadjuvant treatment. Extending this to 
adjuvant treatment seems a natural progression particularly if there is difficulty in 
interpreting the routine pathological analysis following CRT and there is the potential 
for patients who may benefit from further treatment to miss this opportunity.  
Limitations of the study include a lack of information regarding the decision-making 
process for chemotherapy following surgery. Knowledge of whether treatment was 
not recommended or whether it was not offered would have given further 
understanding of any variability in practise. There was was no information on the 
severity or extent of any surgical complications. These are  known to be a factor in 
delaying or withholding adjuvant treatment and may have played a role in the 
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present study. Understandably, if a patient has endured difficult complex treatment, 
he or she is less likely to consider further therapy particularly if there is a risk of 
morbidity. Furthermore, to quantify the effect of adjuvant chemotherapy most 
accurately the ideal study design would be a randomized prospective study with a 
larger number of patients. The present retrospective study will inherently contain 
some degree of selection bias on which patients were offered chemotherapy 
although the matching of the two group goes some way to diminish for this. A further 
limitation is the primary outcome measure of using DFS which does not account for 
death from other causes. This confounding factor has the potential to bias the results 
although in these numbers this is unlikely and 3-year DFS is widely considered a 
good measure of survival.  
The present study has provided further evidence that there may be certain patients 
who will benefit from adjuvant treatment. It is also the first study to use MRI to select 
patients deemed  to be at ‘high-risk’ meaning that decisions to intensify treatment 
can be tailored before surgery when compliance may be improved, although the 
numbers are too small to make definitive recommendations on chemotherapy in 
such patients. 
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Figure 1 – MRI sections showing extramural venous invasion (EMVI) following treatment with chemoradiation. The red arrows 
show the precise location of the extramural veins containing tumour signal. 
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Table 1 - Cohort characteristics in patients receiving and not receiving adjuvant chemotherapy 
 
  Adjuvant 
chemotherapy 
Observation    
  N (%) n (%) Total P-value 
Age <70 98 (62) 48 (70) 146  
 >70 60 (38) 21 (30) 81 0.30 
Performance status 0-1 144 (91) 62 (90) 206  
 2-3 14 (9) 7 (10) 21 0.14 
Gender Female 45 (28) 28 (41) 73  
 Male 113 (72) 41 (59) 154 0.09 
Pathological T-stage pT0-2 32 (20) 19 (28) 51  
 pT3-4 126 (80) 50 (72) 176 0.34 
Nodal status Negative 110 (70) 48 (70) 158  
 Positive 48 (30) 21 (30) 69 0.95 
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Table 2 – Drugs used in Adjuvant chemotherapy   
 
No of patients Capecitabine Capecitabine and 
Oxaloplatin 
5-FU only FOLFOX Other 
Total (n=144) 47 34 6 45 12 
 
 
 
Figure 2 – Kaplin Meier Curves showing Disease-Free Survival in patients receiving 
(green) and not receiving (blue) chemotherapy 
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Table 3  Fully adjusted multivariable Cox’s proportional hazard model for 3 year disease free 
survival (DFS)  
 
  
HR 95% CI lower 95% CI upper p value 
Gender Female Ref 
   
 
Male 1.125 0.668 1.895 0.657 
Pathological T-stage T0 Ref 
   
 
T1 1.633 .234 5.048 .914 
 T2 .822 .217 18.302 .543 
 T3 2.571 .210 3.508 .831 
 T4 1.270 .940 6.951 .066 
Pathological N-stage Negative Ref 
    Positive 1.372 0.799 2.353 .252 
CRM Negative Ref 
   
 
Positive 3.891 1.642 9.174 0.02 
Performance status 0 Ref    
 
1 1.837 .518 .146 .309 
 
2 1.376 .393 .112 .144 
 
3 2.085 .488 .114 .333 
Adjuvant chemotherapy No Ref    
 Yes 0.458 0.271 0.775 .004 
pEMVI Negative Ref    
 Positive 2.041 1.168 3.559 .012 
Age Below 70 Ref    
 Above 70 0.997 0.975 1.019 .765 
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